Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neptune Technologies & Bioressources Inc. - NTB.V -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (230)	4/28/2014 10:46:26 AM
From: Sultan	1 Recommendation Recommended By The Ox Respond to of 902

I think the factory blowup and subsequent disruption to their business momentum which was picking up speed prior to that may have sapped his energy.. I do think time is right for each unit to have a separate CEO.. With Haywood and company making noises prior to AGM and BOD which is due in few weeks, this is a good time if they can find a mover and shaker with good reputation..

To: The Ox who wrote (230)	5/1/2014 11:27:47 AM
From: Sultan	Respond to of 902

Acasti to Present at Two Scientific Forums Laval, Québec, CANADA – May 1, 2014 – Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ:ACST – TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today that it will be presenting at two upcoming scientific forums. The presentations will be on Acasti’s Phase II Open Label (COLT) trial results, previously announced in August 2013. The conferences include: · The National Lipid Association Scientific Sessions 2014 to be held in Orlando, Florida from May 1-4, 2014. Acasti will present on Friday, May 2 from 11:30 to 12:30 and Saturday, May 3 from 12:00 to 1:00 · The 82nd Congress of the European Atherosclerosis Society to be held in Madrid, Spain from May 31-June 3, 2014. Acasti will present on Sunday, June 1 from 12:30 to 3:00 and Monday, June 2 from 12:30 to 3:00 The presentation will be available on the investor section of Acasti’s website under events and presentations, at the conclusion of the National Lipid Association conference: acastipharma.com/en/investor-relations/events

To: The Ox who wrote (230)	5/5/2014 1:06:19 AM
From: Sultan	1 Recommendation Recommended By The Ox Respond to of 902

Acasti Presents at National Lipid Association Scientific Sessions (May 1-4, 2014) Topic: Phase II Open Label (COLT) Trial Results acastipharma.com

To: The Ox who wrote (230)	5/8/2014 11:17:41 AM
From: Sultan	Respond to of 902

Neptune Receives CSST Report LAVAL, Quebec, May 8, 2014 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") ( NEPT) ( NTB.TO), announced today the release of the investigative report on the accident that took place November 8, 2012 at the Sherbrooke production plant. The report, made public by the Commission de la sante et de la securite du travail ("CSST") (the Quebec commission overseeing health and safety in the workplace), outlines the facts and alleged conclusions of the investigation and attributes some responsibility to the company. The report highlights that the exact cause of the accident could not be identified. In addition, it does not make any mention of additional fines or penalties against Neptune beyond the statement of offense notice seeking payment of a fine of approximately $60,000, previously received and disclosed by Neptune in the Fall of 2013. Throughout the investigation, which lasted almost eighteen months, the construction contractors and their employees, as well as the employees and management at Neptune, offered their full cooperation to investigators from the CSST. "We will take the time to analyze the report before commenting further on the conclusions surrounding the causes and circumstances that could have caused this tragic accident," said Andre Godin, Chief Financial Officer of Neptune. "The safety of our employees is one of Neptune's most important concerns." During the reconstruction of the plant, Neptune worked in close collaboration with CSST representatives. Recommendations and corrective measures sought by the CSST were implemented by Neptune in order to make operations at the new plant as safe as possible. finance.yahoo.com

To: The Ox who wrote (230)

5/8/2014 11:23:47 AM

From: Sultan

1 Recommendation

Recommended By
The Ox

Respond to of 902

Photo Release -- Neptune Provides Update on Plant Operating Permits

LAVAL, Quebec, May 8, 2014 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") ( NEPT) ( NTB.TO), provided an update today on the status of operating permits for its Sherbrooke, Quebec, Canada plant.


	Neptune New Production Plant www.neptunebiotech.com

A photo accompanying this release is available at globenewswire.com

As previously announced, Neptune expects to resume production upon receipt of all outstanding permits for its new production facility. To date, the municipal fire department has approved the plant's emergency evacuation plan and no further approvals are required from them. In addition, the Minister of Environment is expected to issue its permit upon notification that the Commission de la sante et de la securite du travail ("CSST"), the Quebec commission overseeing health and safety in the workplace has confirmed the plant conforms to all safety regulations.

During the most recent inspection of the plant by the CSST, certain items were identified that are readily addressable and the facility will be open once the requirements are met. Accordingly, Neptune is targeting an early June 2014 plant opening.

finance.yahoo.com

To: The Ox who wrote (230)	5/16/2014 1:28:04 PM
From: Sultan	1 Recommendation Recommended By The Ox Respond to of 902

Neptune Announces Proposed Director Nominees for Its Upcoming Annual General Meeting finance.yahoo.com

To: The Ox who wrote (230)	5/21/2014 6:16:49 PM
From: Sultan	1 Recommendation Recommended By The Ox Respond to of 902

Neptune Announces Fourth Quarter and Fiscal Year Results finance.yahoo.com Acasti Announces Fourth Quarter and Fiscal Year Results finance.yahoo.com

To: The Ox who wrote (230)	5/30/2014 10:58:42 AM
From: Sultan	Read Replies (1) \| Respond to of 902

I was expecting this but the scale of claims are ridiculous.. Neptune Technologies Says Former CEO Seeks $8.5 Mln Cash and Shares For Constructive Dismissal: Shares Gain on Slim Pre-Bell Volume2 hours ago08:30 AM EDT, 05/30/2014 (MT Newswires) -- Neptune Technologies & Bioressources Inc. (NEPT, NTB.TO) said former president and CEO Henri Harland has filed a lawsuit against the company and its subsidiaries, claiming $8.5 million in damages for constructive dismissal. Harland resigned from his post as CEO of Neptune and its Acasti Pharma (ACST) and NeuroBiosciences units on on April 28, 2014. Harland is also seeking 500,000 new shares of each of Neptune, Acasti Pharma and NeuroBio as well as two blocks of 1,000,000 call options each on the shares held by Neptune in Acasti and NeuroBio. Neptune said the claim, as formulated, is without merit or cause and said it will vigorously defend the lawsuit. Harland has been requested to resign as director. The companies appointed Andre Godin as interim CEO on May 23rd. Neptune stock is up 3.6% pre-market in light trade at $2.55, while Acasti is unchanged.